Aldeyra to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., Chief Financial Officer Joshua Reed, and Chief Commercial Officer David McMullin will be participating in a fireside chat and hosting one-on-one meetings at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit, which is being held in a virtual format.
The fireside chat is scheduled to begin at 2:30 p.m. ET Wednesday, September 23, 2020. A live webcast of the event will be available on the investor relations page of the company's corporate website at https://ir.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.
Guanajuato Silver Company Ltd. (the "Company" or "GSilver") announces a brokered, best-efforts Listed Issuer Financing Exemption private placement (the "Offering") consisting of units of the Company (the "Units") at a price of C$0.20 per Unit (the...
Customers Bancorp, Inc. :
First Quarter 2024 Highlights
Q1 2024 net income available to common shareholders was $45.9 million, or $1.40 per diluted share; ROAA was 0.94% and ROCE was 12.08%.
Q1 2024 core earnings* were $46.5 million, or $1.42...
Petrolympic Ltd. (the "Company", TSXV: PCQ) wishes to announce it has completed a non-brokered private placement (the "Offering") of 5,000,000 common shares of the Company on a flow-through basis ("FT Shares") at a price of $0.08 per FT Share, for...
Agnico Eagle Mines Limited ("Agnico Eagle" or the "Company") today reported financial and operating results for the first quarter of 2024.
"Building on a very strong close to 2023, we are reporting our second consecutive quarter of record...
OP Bancorp (the "Company") , the holding company of Open Bank (the "Bank"), today reported its financial results for the first quarter of 2024. Net income for the first quarter of 2024 was $5.23 million, or $0.34 per diluted common share, compared...
Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") .
Class Period: February 18, 2022 ?...